Onset of Type 1 Diabetes
Advances in the Delayed-Onset of Type 1 Diabetes:
Strategies to Improve Awareness and Care for the Practicing Clinician
Guidelines and Practice Parameters
Resource
| Resource | Address |
|---|---|
| American Diabetes Association Professional Practice Committee.2. Diagnosis and classification of diabetes: Standards of care in diabetes-2024.Diabetes Care.2024;47(suppl 1):S20-S42. | https://diabetesjournals.org/care/article/47/Supplement1/S20/153954 |
| American Diabetes Association Professional Practice Committee.3. Prevention or delay of diabetes and associated comorbidities: Standards of care in diabetes-2024.Diabetes Care.2024;47(suppl 1):S43-S51. | https://diabetesjournals.org/care/article/47/Supplement1/S43/153945 |
| Besser REJ,Bell KJ,Couper JJ,et al.ISPAD Clinical Practice Consensus Guidelines 2022:Stages of type 1 diabetes in children and adolescents.Pediatr Diabetes.2022;23:1175-1187. | https://cdn.ymaws.com/www.ispad.org/resource/resmgr/consensus guidelines 2018/guidelines2022/ch.2pediatric diabetes-2.pdf |
| Mehta S,Ryabets-Lienhard A,Patel N,et al.Pediatric Endocrine Society statement on considerations for the use of teplizumab in clinical practice.Horm Res Paediatr.2024;Apr 30:1-12. | https://pubmed.ncbi.nlm.nih.gov/38663372/ |
| Philip M,Achenbach P,Addala A,et al.Consensus guidance for monitoring individuals with islet autoantibody-positive pre-stage 3 type 1 diabetes.Diabetes Care.2024;Jun 24:dci240042. | https://pubmed.ncbi.nlm.nih.gov/38912694/ |
References/Reading List
Resource
| Resource | Address |
|---|---|
| Atkinson MA, Mirmira RG. The pathogenic "symphony" in type 1 diabetes: A disorder of the immune system,β cells,and exocrine pancreas. Cell Metab.2023;35:1500-1518. | https://pubmed.ncbi.nlm.nih.gov/37478842/ |
| Bogun MM,Bundy BN,Goland RS,Greenbaum CJ.C-peptide levels in subjects followed longitudinally before and after type 1 diabetes diagnosis in TrialNet.Diabetes Care.2020;43:1836-1842. | https://pubmed.ncbi.nlm.nih.gov/32457058/ |
| Fyvie MJ,Gillespie KM.The importance of biomarker development for monitoring type 1 diabetes progression rate and therapeutic responsiveness.Front Immunol.2023;14:1158278. | https://pubmed.ncbi.nlm.nih.gov/37256143/ |
| Herold KC,Bundy BN,Long SA,et al.An anti-CD3 antibody,teplizumab,in relatives at risk for type 1 diabetes.N Engl J Med.2019;381:603-613. | https://pubmed.ncbi.nlm.nih.gov/31180194/ |
| Herold KC,Gitelman SE,Gottlieb PA,et al.Teplizumab:A disease-modifying therapy for type 1 diabetes that preserves β-Cell function.Diabetes Care.2023;46:1848-1856. | https://pubmed.ncbi.nlm.nih.gov/37607392/ |
| Holt RIG, DeVries JH, Hess-Fischl A, et al. The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes(EASD).Diabetes Care.2021;44:2589-2625. | https://pubmed.ncbi.nlm.nih.gov/34593612/ |
|---|---|
| Insel RA,Dunne JL,Atkinson MA,et al. Staging presymptomatic type 1 diabetes:A scientific statement of JDRF,the Endocrine Society,and the American Diabetes Association.Diabetes Care.2015;38:1964-1974. | https://pubmed.ncbi.nlm.nih.gov/26404926/ |
| Katsarou A,Gudbjörnsdottir S,Rawshani A,et al.Type 1 diabetes mellitus.Nat Rev Dis Primers.2017;3:17016. | https://pubmed.ncbi.nlm.nih.gov/28358037/ |
| Leslie RD,Evans-Molina C,Freund-Brown J,et al.Adultonset type 1 diabetes:Current understanding and challenges.Diabetes Care.2021;44:2449-2456. | https://pubmed.ncbi.nlm.nih.gov/34670785/ |
| Linsley PS,Greenbaum CJ,Nepom GT.Uncovering pathways to personalized therapies in type 1 diabetes.Diabetes.2021;70:831-841. | https://pubmed.ncbi.nlm.nih.gov/33741606/ |
| O'Donnell HK,Rasmussen CG,Dong F,et al.Anxiety and risk perception in parents of children identified by population screening as high risk for type 1 diabetes.Diabetes Care.2023;46:2155-2161. | https://pubmed.ncbi.nlm.nih.gov/37673098/ |
| Ospelt E,Hardison H,Rioles N,et al.Understanding providers'readiness and attitudes toward autoantibody screening:A mixed-methods study.Clin Diabetes.2024;42:17-26. | https://pubmed.ncbi.nlm.nih.gov/38230325/ |
| Ramos EL,Dayan CM,Chatenoud L,et al.Teplizumab andβ-Cell function in newly diagnosed type 1 diabetes.N Engl J Med.2023;389:2151-2161. | https://pubmed.ncbi.nlm.nih.gov/37861217/ |
| Simmons KM,Sims EK.Screening and prevention of type1 diabetes:Where are we?J Clin Endocrinol Metab.2023;108:3067-3079. | https://pubmed.ncbi.nlm.nih.gov/37290044/ |
| Simmons KMW,Frohnert BI,O'Donnell HK,et al.Historical insights and current perspectives on the diagnosis and management of presymptomatic type 1 diabetes.Diabetes Technol Ther.2023;25:790-799. | https://pubmed.ncbi.nlm.nih.gov/37695674/ |
| Sims EK,Besser REJ,Dayan C,et al.Screening for type1 diabetes in the general population:A status report and perspective.Diabetes.2022;71:610-623. | https://pubmed.ncbi.nlm.nih.gov/35316839/ |
| Sims EK,Bundy BN,Stier K,et al.Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals.Sci Transl Med.2021;13:aebc8980. | https://pubmed.ncbi.nlm.nih.gov/33658358/ |
| Smigoc Schweiger D.Recent advances in immune-based therapies for type1 diabetes.Horm Res Paediatr.2023;96:631-645. | https://pubmed.ncbi.nlm.nih.gov/35533645/ |
| VanBuecken D,Lord S,Greenbaum CJ.Changing the course of disease in type1 diabetes.In:Feingold KR,Anawalt B,Blackman MR,eds.Endotext[Internet].MDText.com;January 6,2022. | https://www.ncbi.nlm.nih.gov/books/NBK326738/ |
Resources and Societies
Resource
| Resource | Address |
|---|---|
| American Diabetes Association®. Summary of the American Diabetes Association® Type 1 Diabetes Screening & Awareness Roundtable. December 15,2023. | https://diabetes.org/sites/default/files/2024-04/ADA-T1D-Screening-and-Awareness-Roundtable-Report.pdf |
| ASK(Autoimmunity Screening for Kids).T1D screening program. | https://www.askhealth.org/ |
| Breakthrough T1D.Enrolling in Clinical Trials. | https://www.breakthrought1d.org/clinical-trials/ |
| Breakthrough T1D.Breakthrough T1D Early detection. | https://www.breakthrought1d.org/early-detection/ |
| CASCADE Research Study.Type 1 diabetes and celiac disease screening for children in the state of Washington. | https://cascadekids.org/ |
| Sanford Research.PLEDGE Pediatric Screening Program. | https://research.sanfordhealth.org/fields-of-research/diabetes/pledge |
| Type 1 Diabetes TrialNet.For Healthcare Providers:TrialNet Recommendations for Clinicians. | https://www.trialnet.org/healthcare-providers |
| Type 1 Diabetes TrialNet.Resources for T1D screening& national T1D screening program. | https://www.trialnet.org/ |
| University of Colorado-Barbara Davis Center for Diabetes.Ask the experts for early T1D answers and guidance. | https://www.asktheexperts.org/ |
All URLs accessed June 24, 2024